These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19934317)

  • 1. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
    Ugel S; Zoso A; De Santo C; Li Y; Marigo I; Zanovello P; Scarselli E; Cipriani B; Oelke M; Schneck JP; Bronte V
    Cancer Res; 2009 Dec; 69(24):9376-84. PubMed ID: 19934317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
    Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
    Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
    Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
    Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.
    Bruns H; Bessell C; Varela JC; Haupt C; Fang J; Pasemann S; Mackensen A; Oelke M; Schneck JP; Schütz C
    Clin Cancer Res; 2015 May; 21(9):2075-83. PubMed ID: 25593301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.
    Chiu YL; Schneck JP; Oelke M
    J Vis Exp; 2011 Apr; (50):. PubMed ID: 21505415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
    Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
    Front Immunol; 2021; 12():674276. PubMed ID: 34566953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
    Chang ML; Chen YT; Su YC; Kung JT
    J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
    Alexander-Miller MA; Leggatt GR; Berzofsky JA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4102-7. PubMed ID: 8633023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
    Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
    Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
    Lu X; Jiang X; Liu R; Zhao H; Liang Z
    Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
    Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
    Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
    Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
    J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
    Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.